Don't forget to vote , Must Be In By 18th November, page-35

Yes Fingers,

There really is a big game on here.
BILLIONS of dollars up for grabs in this game for big Pharmas.

Success in this field is something that is rarely seen when combating viruses.
Viruses are very complex

Success in a HIV-1 Phase 2 trial with no side affects is amazing.

And to be accepted and present BIT 225 HIV-1 Phase 2 data at the upcoming (27th of November 2018) prestigious HIV DART and Emerging Viruses meeting, as a late entry is very encouraging.

BIT 225 is only one compound of many, in the Biotron virus war chest.
Depending on the data and how much better it is than already known results the BIT225 would be worth $10 Billion.

However, if one compound is sold then the knowledge on other compounds that could be made go with BIT 225

There may well be a TO if the data is brilliant and it might be well over $10 BILLION for the whole BIT war chest.

Either way Biotron is in a very strong strategic position right now.

Dr Michelle knows what this is worth.

All IMO of course
MB

Please read all information on Biotron web site.
www.biotron.com.au